VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Porcine Rotavirus Vaccine rPEDV-PoRV-VP7
Vaccine Information
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Antigen: PoRV VP7 (Li et al., 2022)
  • VP7 gene engineering:
    • Type: Recombinant vector construction
    • Description: (Li et al., 2022)
    • Detailed Gene Information: Click Here.
  • Vector: PEDV strain YN150 (Li et al., 2022)
  • Preparation: The recombinant virus was constructed by replacing the entire open reading frame 3 (ORF3) in the genome of an attenuated PEDV strain YN150 with the PoRV VP7 gene using reverse genetic systems. (Li et al., 2022)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Recombinant PEDV expressing PoRV VP7 is an effective bivalent vaccine against PEDV and PoRV in pigs. (Li et al., 2022)
Host Response

Pig Response

  • Vaccination Protocol: Ten 10-day-old piglets were purchased from a pig farm and were randomly divided into two groups (Mock-inoculated group and rPEDV-PoRV-VP7-inoculated group), which were housed in separated containments. Prior to immunization, rectal swabs from all piglets were confirmed negative for PEDV, PoRV, PDCoV, and TGEV by RT-PCR. Neutralizing antibodies against PEDV and PoRV were not detected in the sera of all piglets. After acclimation for 24 h, rPEDV-PoRV-VP7 was inoculated to the vaccinated group at a titer of 5 × 10^6 TCID50/mL (2 mL oral administration and 2 mL intramuscular administration per piglet), while mock-infected piglets were inoculated with the same volume of DMEM medium as a negative control. (Li et al., 2022)
  • Immune Response: The levels of anti-PoRV VP7 and anti-PEDV S IgA antibodies in saliva from rPEDV-PoRV-VP7-inoculated piglets were significantly increased from 14 to 28 days post-inoculation (DPI) compared with mock-inoculated piglets. These results suggest that rPEDV-PoRV-VP7 could effectively induce the specific IgA antibodies against PoRV and PEDV in piglets. Neutralization antibody titers against PoRV were initially detected at 7 DPI and elevated to about 1:97 at 21 DPI, while neutralization antibody titers against PEDV reached 1:8 at 14 DPI and dropped to approximate 1:2 at 28 DPI. (Li et al., 2022)
  • Side Effects: After inoculation, no piglet displayed clinical symptoms such as vomiting, diarrhea, or anorexia. (Li et al., 2022)
References